Literature DB >> 24746829

Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk.

Jordi Merino1, Aleix Sala-Vila2, Richard Kones3, Raimon Ferre4, Núria Plana4, Josefa Girona4, Daiana Ibarretxe4, Mercedes Heras4, Emilio Ros2, Lluís Masana4.   

Abstract

Dietary long-chain n-3 polyunsaturated fatty acids (LCn-3PUFA) improve endothelial function in medium-large-sized arteries, but effects on small peripheral arteries, responsible for most arterial resistance, are little known. We investigated the effects of increasing LCn-3PUFA intake with the usual diet on small artery reactive hyperemia index (saRHI). Within a clinical trial evaluating the effects of 1 year of intensive lifestyle intervention versus standard care on cardiovascular markers in subjects at risk, we selected 108 participants regardless of treatment allocation (n=47 standard care; n=61 intensive intervention) with complete baseline and follow-up information on dietary, clinical, saRHI and biochemical data, including biomarkers of inflammation and endothelial activation. At the end of follow-up, saRHI increased across tertiles of change in dietary LCn-3PUFA. Subjects in the top tertile (increased LCn-3PUFA intake) increased serum ApoA1 and decreased hs-CRP, serum TNF-α, sICAM-1, sVCAM-1 and oxLDL from baseline. After pooling data, in unadjusted models, changes in saRHI significantly correlated to changes in LCn-3PUFA intake and ApoA1 (directly) and changes in systolic blood pressure, waist circumference, TNF-α, sVCAM-1 and sE-selectin (inversely). In a multivariate model, changes in dietary LCn-3PUFA were significantly associated with changes in saRHI [B=0.08 (95% confidence interval=0.083-0.291) for an increase by 100 mg/day]. Systolic blood pressure was inversely associated with saRHI changes [B=-0.203 (-0.441 to -0.029) for a 9-mmHg increase]. We conclude that increased dietary consumption of LCn-3PUFA might be a cost-effective strategy to improve peripheral vasoactivity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Diet; Docosahexaenoic acid; Eicosapentaenoic acid; Endothelial function; Inflammation

Mesh:

Substances:

Year:  2014        PMID: 24746829     DOI: 10.1016/j.jnutbio.2014.02.004

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  6 in total

Review 1.  n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review.

Authors:  Richard Kones; Scott Howell; Umme Rumana
Journal:  Med Princ Pract       Date:  2017-11-29       Impact factor: 1.927

Review 2.  Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Authors:  Richard Kones; Umme Rumana
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

3.  Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord.

Authors:  Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum
Journal:  Annu Rev Nutr       Date:  2020-09-23       Impact factor: 11.848

4.  Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol.

Authors:  Tian Shen; Guoqiang Xing; Jingfen Zhu; Shuxian Zhang; Yong Cai; Donghua Li; Gang Xu; Evan Xing; Jianyu Rao; Rong Shi
Journal:  Lipids Health Dis       Date:  2017-12-27       Impact factor: 3.876

5.  Effects of a Macro-Nutrient Preload on Type 2 Diabetic Patients.

Authors:  Chun-Jun Li; Gunnar Norstedt; Zhao-Gian Hu; Pei Yu; Dai-Qing Li; Jing Li; Qian Yu; Magnus Sederholm; De-Min Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-16       Impact factor: 5.555

Review 6.  Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved.

Authors:  Yasuhiro Watanabe; Ichiro Tatsuno
Journal:  J Atheroscler Thromb       Date:  2019-10-03       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.